Long‐Term Outcomes of BK Viremia in Kidney Transplant Recipients
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70333 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Srijan Tandukar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Renal-Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, Philadelphia, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, BK Virus, Viremia, Polyomavirus Infections. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
BK viremia is associated with worse kidney transplant function and de novo donor‐specific antibodies (DSA), but mortality and graft survival are not impacted in the short‐ and intermediate‐term. The long‐term impact of BK viremia remains unclear.
Methods
We performed a single‐center retrospective study on 1058 consecutive kidney or kidney‐pancreas transplant recipients. We classified the cohort based on the presence or absence of BK viremia, BK viral loads, persistence of BK viremia, and pre‐existing or de novo DSA. Outcomes included mortality, graft loss, death‐censored graft survival (DCGS), estimated glomerular filtration rate, biopsy‐proven acute rejection (BPAR), de novo DSA, ureteral stenosis, and genitourinary (GU) malignancies.
Results
Over a median follow‐up period of 9.7 years, there was no difference in graft loss ( p = 0.08) and mortality ( p = 0.56). Time‐varying multivariable analysis showed no difference in DCGS [HR 1.02, (0.91–1.16)]. Compared to never BK viremic patients, patients with BK viremia had similar graft function at 5 and 10 years ( p = 0.09 and 0.65, respectively), rates of GU malignancies (7.0% vs. 5.2%, p = 0.35) and ureteral stenosis (0.8% vs. 0.4%, p = 0.63). Patients with BK viral loads >10 000 copies/mL had a higher risk of de novo DSA [HR 1.71, (1.08–2.68)] and BPAR [HR 2.11, (1.28–3.47)].
Conclusions
BK viremia did not impact mortality, graft loss, kidney function, GU malignancies, and ureteral stenosis over long‐term follow‐up, but BPAR episodes and development of de novo DSA were higher with viral loads >10 000 copies/mL. Strict monitoring protocols and immunosuppression reduction strategies are effective in minimizing the risk associated with BK viremia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Renal-Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, Philadelphia, USA.
- Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, USA.
- University of Pennsylvania, Philadelphia, USA.
- Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, USA.
- Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, USA.
ORCID-Profile: Srijan Tandukar, Jennifer Trofe, Elizabeth M Sonnenberg, Peter Abt, Vishnu Potluri
Zitieren
APA
Tandukar, S., Wu, Q., Chandrashekar, S., Shah, D., Chiang, C., Couch, K., Trofe, J., Sonnenberg, E. M., Abt, P., Lim, M. A., Potluri, V., & Bloom, R. (2025). Long‐Term Outcomes of BK Viremia in Kidney Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70333
Vancouver
Tandukar S, Wu Q, Chandrashekar S, Shah D, Chiang C, Couch K, et al. Long‐Term Outcomes of BK Viremia in Kidney Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70333
BibTeX
@article{Tandukar2025,
author = {Tandukar, Srijan and Wu, Qufei and Chandrashekar, Sneha and Shah, Divyash and Chiang, Chienhui and Couch, Kathryn and Trofe, Jennifer and Sonnenberg, Elizabeth M and Abt, Peter and Lim, Mary Ann and Potluri, Vishnu and Bloom, Roy},
title = {Long‐Term Outcomes of BK Viremia in Kidney Transplant Recipients},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70333}
}
EUVIMED